HC Wainwright Issues Pessimistic Outlook for NKTR Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Stock analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for Nektar Therapeutics in a research report issued to clients and investors on Monday, August 17th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will earn ($1.91) per share for the quarter, down from their previous estimate of ($1.90). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($8.69) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ FY2026 earnings at ($7.49) EPS, Q2 2027 earnings at ($1.19) EPS, Q4 2027 earnings at ($2.35) EPS, FY2027 earnings at ($8.83) EPS, FY2028 earnings at ($9.52) EPS, FY2029 earnings at ($6.32) EPS and FY2030 earnings at $0.35 EPS.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.74. The firm had revenue of $10.13 million for the quarter, compared to the consensus estimate of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%.

NKTR has been the topic of several other research reports. Citigroup lifted their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Wedbush dropped their price target on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, May 11th. Canaccord Genuity Group started coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $153.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Tuesday, June 2nd. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $150.00.

Nektar Therapeutics Stock Performance

Nektar Therapeutics stock opened at $73.64 on Wednesday. Nektar Therapeutics has a fifty-two week low of $25.34 and a fifty-two week high of $109.00. The stock has a market cap of $2.49 billion, a PE ratio of -10.99 and a beta of 1.14. The firm’s 50-day simple moving average is $68.65 and its 200 day simple moving average is $69.78.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.32, for a total value of $603,200.00. Following the sale, the chief executive officer directly owned 65,045 shares in the company, valued at $3,923,514.40. The trade was a 13.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total value of $397,670.00. Following the transaction, the insider directly owned 9,756 shares in the company, valued at $682,920. This represents a 36.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 21,219 shares of company stock valued at $1,337,082 over the last three months. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 210 shares during the period. KBC Group NV purchased a new position in Nektar Therapeutics in the 1st quarter valued at approximately $52,000. Headlands Technologies LLC bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $65,000. State of Wyoming purchased a new stake in shares of Nektar Therapeutics during the first quarter worth $67,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Nektar Therapeutics in the first quarter worth $68,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.